Orgenesis Inc. (ORGS): Price and Financial Metrics
ORGS Stock Summary
- ORGS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.89 -- higher than merely 6.49% of US-listed equities with positive expected earnings growth.
- With a year-over-year growth in debt of -41.92%, Orgenesis Inc's debt growth rate surpasses only 7.74% of about US stocks.
- Revenue growth over the past 12 months for Orgenesis Inc comes in at -48.14%, a number that bests only 6.27% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Orgenesis Inc are AMBA, IPHI, IONS, XBIT, and ARWR.
- Visit ORGS's SEC page to see the company's official filings. To visit the company's web site, go to www.orgenesis.com.
ORGS Stock Price Chart Interactive Chart >
ORGS Price/Volume Stats
| Current price | $7.07 | 52-week high | $8.20 |
| Prev. close | $7.05 | 52-week low | $2.76 |
| Day low | $7.00 | Volume | 45,676 |
| Day high | $7.25 | Avg. volume | 182,807 |
| 50-day MA | $5.98 | Dividend yield | N/A |
| 200-day MA | $5.66 | Market Cap | 170.78M |
Orgenesis Inc. (ORGS) Company Bio
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.
Latest ORGS News From Around the Web
Below are the latest news stories about Orgenesis Inc that investors may wish to consider to help them evaluate ORGS as an investment opportunity.
Orgenesis to Present Today at the Winter Wonderland Conference-Best Ideas from the Buy-SideGERMANTOWN, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th - February 19th, 2021. Vered Caplan, CEO of Orgenesis, is scheduled to present today, February 16th, 2021 at 2:30 PM, Eastern Time. The presentation will be webcast live and available for replay here. One-on-one meetings will be held throughout the conference via video conference calls. About the Winter Wonderland ConferenceThe MicroCap Rodeo is hosting its “Winter Wonderland Conference- Best Ideas Bowl,” with 25-minute virtual presentations ... |
Did Orgenesis' (NASDAQ:ORGS) Share Price Deserve to Gain 44%?If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than... |
Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related TransactionIcellator® commercially available for lipotransfer in first two countries with more approvals expectedGERMANTOWN, Md., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced completion of the previously announced acquisition of Koligo Therapeutics, Inc. (“Koligo”), a regenerative medicine company. Additionally, the Company announced that it has acquired substantially all of the assets of Tissue Genesis, LLC (“Tissue Genesis”), adding to a growing list of POCare technology resources. The acquisition of Tissue Genesis was initially undertaken via Koligo Therapeutics, Inc., and became part of the Koligo acquisition transaction. Orgenesis will n... |
Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare PlatformProvides update on COVID-19 therapeutic programs Reports cash and cash equivalents of $97.5 million as of June 30, 2020 GERMANTOWN, Md., Aug. 07, 2020 … |
Health Check: How Prudently Does Orgenesis (NASDAQ:ORGS) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... |
ORGS Price Returns
| 1-mo | 8.60% |
| 3-mo | 60.68% |
| 6-mo | 43.70% |
| 1-year | 68.33% |
| 3-year | -12.68% |
| 5-year | 90.05% |
| YTD | 57.11% |
| 2020 | -3.43% |
| 2019 | -0.43% |
| 2018 | -18.68% |
| 2017 | 54.65% |
| 2016 | -3.09% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...